ERBB2 and breast carcinoma: On the other hand, no statistically significant associations were found in AA breast cancer patients for neither of the HER2-overexpressing tumors (luminal/HER2 = 1.03, 95% CI, 0.68-1.56; p= 0.862HER2-enriched=1.46, 95% CI, 0.74-2.88, p= 0.273).